KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Equity: 2011-2025

Historic Return on Equity for Halozyme Therapeutics (HALO) over the last 14 years, with Sep 2025 value amounting to 1.42%.

  • Halozyme Therapeutics' Return on Equity rose 37.00% to 1.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.42%, marking a year-over-year increase of 37.00%. This contributed to the annual value of 1.98% for FY2024, which is 24.00% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Return on Equity of 1.42% as of Q3 2025, which was up 4.09% from 1.37% recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Return on Equity high stood at 2.44% for Q2 2021, and its period low was 1.06% during Q3 2024.
  • Over the past 3 years, Halozyme Therapeutics' median Return on Equity value was 1.42% (recorded in 2025), while the average stood at 1.51%.
  • In the last 5 years, Halozyme Therapeutics' Return on Equity spiked by 293bps in 2021 and then crashed by 129bps in 2025.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Return on Equity stood at 1.68% in 2021, then dropped by 17bps to 1.52% in 2022, then rose by 18bps to 1.69% in 2023, then tumbled by 60bps to 1.09% in 2024, then spiked by 37bps to 1.42% in 2025.
  • Its Return on Equity was 1.42% in Q3 2025, compared to 1.37% in Q2 2025 and 1.15% in Q1 2025.